Frank Craig Interviewed in DDW Article
Where is the drug discovery expertise happening in the UK?
PUBLISHED IN
ARTICLE TITLE
AUTHOR
PUBLICATION DATE
FEATURED EXPERT
DDW
Where is the drug discovery expertise happening in the UK?
Megan Thomas
October 16, 2023
Frank Craig, CEO, Sphere Fluidics*
The UK is a global leader in drug discovery, with expertise spread across multiple regions beyond the renowned ‘Golden Triangle’ of London, Oxford, and Cambridge.
This cluster benefits from world-class universities and a thriving biotech ecosystem, attracting talent, investment, and innovation.
Dr. Frank Craig, CEO of Sphere Fluidics*, highlights the UK’s strength in pharmaceutical and biotech sectors, noting the presence of approximately 12 drug discovery clusters nationwide. He emphasizes that successful biotech and pharma companies, including Sphere Fluidics*, strategically base themselves near universities, hospitals, investors, and essential facilities to access resources critical for growth. Sphere Fluidics’* recent expansion to Granta Park, a leading science park in Cambridgeshire, exemplifies this approach and the collaborative environment fostered by major pharma and mid-size biotech partnerships.
Frank Craig, CEO
“The UK is world class in the pharmaceutical and biotech sectors, with drug discovery clusters in circa 12 regions across the UK. To create a new pharma or biotech company takes an entrepreneurial idea, investment, facilities, employees, and IP. Due to the need for these factors, many companies, including Sphere Fluidics*, base themselves nearby universities and/or hospitals, investors, and facilities.”
Key Notes
The UK hosts about 12 drug discovery clusters nationwide, showing a broad and diverse innovation ecosystem beyond just the Golden Triangle.
Biotech firms like Sphere Bio locate near universities, hospitals, investors, and science parks to boost access to talent and partnerships.
Sphere Bio’s expansion to Granta Park highlights the importance of leading science parks in supporting biotech growth and collaboration.
Strong collaboration between pharma, mid-size biotechs, and startups in the UK fuels innovation and strengthens the drug discovery sector.
For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.
This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.
Stay ahead with Sphere Bio
Join our community of forward-thinking scientists. Stay informed with the latest breakthroughs, product launches, and industry research. Subscribe to our newsletter and be the first to know about innovations that can transform your lab.
